Cargando…

Self-Assembled Nanoparticles Prepared from Low-Molecular-Weight PEI and Low-Generation PAMAM for EGFRvIII-Chimeric Antigen Receptor Gene Loading and T-Cell Transient Modification

BACKGROUND: The complex preparation procedures and severe toxicities are two major obstacles facing the wide use of chimeric antigen receptor-modified T (CAR-T) cells in clinical cancer immunotherapy. The nanotechnology-based T cell temporary CAR modification may be a potential approach to solve the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Qianru, Zhang, Maxin, Chen, Yuetan, Chen, Xiaolong, Shi, Sanyuan, Sun, Kang, Ye, Ran, Zheng, Yuan, Chen, Yang, Xu, Yuhong, Peng, Jinliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986680/ https://www.ncbi.nlm.nih.gov/pubmed/32158206 http://dx.doi.org/10.2147/IJN.S229858

Ejemplares similares

EGFRvIII: the promiscuous mutation
por: Greenall, Sameer A, et al.
Publicado: (2016)

Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma
por: Sahin, Ayguen, et al.
Publicado: (2018)

Development of an EGFRvIII specific recombinant antibody
por: Gupta, Puja, et al.
Publicado: (2010)

Efficacy of osimertinib against EGFRvIII+ glioblastoma
por: Chagoya, Gustavo, et al.
Publicado: (2020)

Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII(+)PTEN(−) glioblastoma in vivo
por: Xu, Wen, et al.
Publicado: (2016)

Synergistic antitumor efficacy against the EGFRvIII(+)HER2(+) breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12
por: Xu, Wen, et al.
Publicado: (2015)

Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma
por: Ren, Pei-pei, et al.
Publicado: (2017)

The natural history of EGFR and EGFRvIII in glioblastoma patients
por: Heimberger, Amy B, et al.
Publicado: (2005)

Targeting FHL2 for EGFRvIII-positive glioblastoma
por: Sun, Lili, et al.
Publicado: (2018)

Will EGFRvIII and neuronal-derived EGFR be targets for imipramine?
por: Li, Zesheng, et al.
Publicado: (2023)

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
por: Padfield, Emily, et al.
Publicado: (2015)

EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma
por: Taher, Mohiuddin M., et al.
Publicado: (2020)

The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis
por: Hoogstrate, Youri, et al.
Publicado: (2021)

Phenotypical Flexibility of the EGFRvIII-Positive Glioblastoma Cell Line and the Multidirectional Influence of TGFβ and EGF on These Cells—EGFRvIII Appears as a Weak Oncogene
por: Włodarczyk, Aneta, et al.
Publicado: (2022)

Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma
por: Abbott, Rebecca C, et al.
Publicado: (2021)

Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma
por: Abbott, Rebecca C, et al.
Publicado: (2021)

Challenges in EGFRvIII Detection in Head and Neck Squamous Cell Carcinoma
por: Wheeler, Sarah E., et al.
Publicado: (2015)

EGFRvIII Is Expressed in Cellular Areas of Tumor in a Subset of Glioblastoma
por: NOZAWA, Takanori, et al.
Publicado: (2019)

GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma
por: Choi, Justin, et al.
Publicado: (2022)

Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma
por: Abbott, Rebecca C, et al.
Publicado: (2023)

LncRNAs and EGFRvIII sequestered in TEPs enable blood-based NSCLC diagnosis
por: Luo, Chang-Liang, et al.
Publicado: (2018)

Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma
por: Wang, Sumei, et al.
Publicado: (2018)

Development of chimeric antigen receptor (CAR) T-cell immunotherapy for glioblastoma targeting epidermal growth factor receptor variant III (EGFRvIII)
por: Park, Anthony K, et al.
Publicado: (2015)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells
por: Struve, Nina, et al.
Publicado: (2015)

Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma
por: Velpula, Kiran K., et al.
Publicado: (2017)

Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition
por: Shen, Ying, et al.
Publicado: (2015)

Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells
por: Zhang, Xingmei, et al.
Publicado: (2018)

Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells
por: Zhang, Xingmei, et al.
Publicado: (2023)

Pre-clinical validation of a humanized anti-EGFR variant III chimeric antigen receptor and phase I trial of CART-EGFRvIII in glioblastoma
por: Johnson, Laura A, et al.
Publicado: (2014)

A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII
por: Trembath, Dimitri G, et al.
Publicado: (2007)

Cyclic trans-phosphorylation in a homodimer as the predominant mechanism of EGFRvIII action and regulation
por: Stec, Wojciech, et al.
Publicado: (2018)

Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies
por: Ellwanger, Kristina, et al.
Publicado: (2017)

Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma
por: Appolloni, Irene, et al.
Publicado: (2021)

Highly Sensitive EGFRvIII Detection in Circulating Extracellular Vesicle RNA of Glioma Patients
por: Batool, Syeda Maheen, et al.
Publicado: (2022)

EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma
por: Miao, Hongsheng, et al.
Publicado: (2014)

Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma
por: Shen, Chan-Juan, et al.
Publicado: (2013)

Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma
por: Schmidts, Andrea, et al.
Publicado: (2022)

Is membranous location of EGFR or EGFRvIII immunostaining associated with good prognosis in renal cell carcinoma?
por: Modjtahedi, H, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_i1dubbhp4k65qb55akbav81tg2